{{Infobox drug
| drug_name = 
| IUPAC_name        = 4-[(''E'')-2-[5,5,8,8-tetramethyl-3-(1''H''-pyrazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]ethenyl]benzoic acid
| image             = Palovarotene2DACS.svg
| width             = 200px

<!-- Clinical data -->
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Investigational
| routes_of_administration = Oral

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         =

<!-- Identifiers -->
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 10295295
| ChemSpiderID      = 8470763

<!-- Chemical data -->
| C=27 | H=30 | N=2 | O=2
| molecular_weight  = 414.5393 g/mol
| smiles = CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C
| StdInChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
| StdInChIKey = YTFHCXIPDIHOIA-DHZHZOJOSA-N
}}

'''Palovarotene''' is a highly selective [[retinoic acid receptor gamma]] (RAR-γ) [[agonist]] that is under investigation as a potential treatment for [[fibrodysplasia ossificans progressiva]] (FOP), an ultra-rare and severely disabling genetic disease characterized by extra-skeletal bone formation ([[heterotopic ossification]] or HO) in muscle and soft tissues.<ref>{{cite web|title=FOP Fact Sheets|url=http://www.ifopa.org/fop-fact-sheet.html|website=www.ifopa.org|accessdate=11 April 2016}}</ref>

Palovarotene is being developed by Clementia Pharmaceuticals and was granted Fast Track and [[orphan drug]] designations by the United States [[Food and Drug Administration]] for the treatment of FOP and Orphan Medicinal Product Designation by the [[European Medicines Agency]] (EMA) in 2014.<ref>{{cite web|title=Public summary of opinion on orphan designation. Palovarotene for the treatment of fibrodysplasia ossificans progressiva.|url=http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/01/WC500180398.pdf|website=www.ema.europa.eu|publisher=Committee for Orphan Medicinal Products|accessdate=11 April 2016}}</ref><ref>{{cite news|title=Clementia Pharmaceuticals Receives Fast Track Designation for Palovarotene for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)|url=http://www.prnewswire.com/news-releases/clementia-pharmaceuticals-receives-fast-track-designation-for-palovarotene-for-treatment-of-fibrodysplasia-ossificans-progressiva-fop-300001808.html|accessdate=11 April 2016|publisher=PRNewswise|date=1 December 2014}}</ref><ref>{{cite news|title=Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva|url=http://www.prnewswire.com/news-releases/clementia-pharmaceuticals-receives-ema-orphan-medicinal-product-designation-for-palovarotene-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-283465711.html|accessdate=11 April 2016|publisher=PRNewswire|date=21 November 2014}}</ref> [[Phases_of_clinical_research#Phase_II|Phase II]] clinical studies yielded positive results.<ref>{{cite news|title=Clementia Pharmaceuticals Initiates Phase 2 Study of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)|url=https://www.reuters.com/article/idUSnMKWyl8vka+1c0+MKW20140714|accessdate=11 April 2016|publisher=Marketwired|date=14 July 2014}}</ref><ref>Marriott, Niamh.  [https://www.europeanpharmaceuticalreview.com/44656/news/industry-news/fibrodysplasia-ossificans-trial/ "Success for Clementia’s Phase II Fibrodysplasia Ossificans Progressiva trial"], ''[[European Pharmaceutical Review]]'' (October 16, 2016).</ref>

== History ==

Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD).<ref>{{cite journal|title=Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema|journal=Current Opinion in Investigation Drugs|date=November 2009|volume=10|issue=11|pages=1243–1250|pmid=19876792|author1=Hind, M |author2=Stinchcombe, S }}</ref> A one-year trial did not demonstrate a significant benefit on lung density in moderate-to-severe emphysema secondary to severe α(1)-antitrypsin deficiency.<ref>{{cite journal|title=Randomised controlled trial for emphysema with a selective agonist of the c-type retinoic acid receptor|journal=European Respiratory Journal|date=August 2012|doi=10.1183/09031936.00161911|pmid=22282548|volume=40|issue=2|pages=306–312|author1=Stolk, J |author2=Stockley, RA |author3=Stoel, BC |author4=Cooper, BG |author5=Piitulainen, E |author6=Seersholm, N |author7=Chapman, KR |author8=Burdon, JG |author9=Decramer, M |author10=Abboud, RT |author11=Mannes, GP |author12=Wouters, EF |author13=Garrett, JE |author14=Barros-Tizon, JC |author15=Russi, EW |author16=Lomas, DA |author17=MacNee, WA |author18=Rames, A }}</ref>

In 2011, animal studies demonstrated that RARγ agonists, including palovarotene, blocked new bone formation in both an injury-induced mouse model of heterotopic ossification (HO) and a genetically modified biological mouse model of FOP containing a continuously active ACVR1/ALK2 receptor in a dose-dependent manner.<ref>{{cite journal|last1=Shimono|title=Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-y agonists|journal=Nature Medicine|date=2011|volume= 17|issue=4|pages=454–460|doi=10.1038/nm.2334|display-authors=etal}}</ref><ref>{{cite journal|last1=Kaplan FS and Shore EM|title=Derailing heterotopic ossification and RARing to go|journal=Nature Medicine|date=2011|volume= 17|issue=4|page=420|doi=10.1038/nm0411-420|pmid=21475232|pmc=4913781}}</ref> A 2016 study demonstrated that palovarotene also inhibited spontaneous heterotopic ossification, maintained limb mobility and functioning, and restored skeletal growth in FOP mouse models.<ref>{{cite journal|last1=Chakkalakal|title=Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation|journal=J Bone Miner Res.|date=2016|doi=10.1002/jbmr.2820|display-authors=etal}}</ref>

Palovarotene is currently being investigated as a potential therapy for FOP, a disorder of heterotopic ossification, in humans, beginning phase 2 clinical trials for human testing in July 2014.<ref>{{Cite web|url=http://clementiapharma.com/clementia-pharmaceuticals-initiates-phase-2-study-of-palovarotene-in-patients-with-fibrodysplasia-ossificans-progressiva-fop/|title=Clementia Pharmaceuticals Initiates Phase 2 Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva (FOP) - Clementia Pharma|website=clementiapharma.com|access-date=2014-07-24}}</ref>

Phase 3 clinical trials are currently planned for implementation in the second half of 2017.

==References==
{{Reflist|2}}


{{Retinoid receptor modulators}}

[[Category:Retinoids]]
[[Category:Pyrazoles]]
[[Category:Benzoic acids]]
[[Category:Tetralins]]


{{respiratory-system-drug-stub}}